Avalon GloboCare Corp. (NASDAQ: AVCO) (“Avalon” or “the Company”), a clinical-stage global developer of cell-based technologies and therapeutics, announced that it has entered into a definitive agreement to acquire Hebei Senlang Biotechnology Co. Ltd. (“SenlangBio”), a PRC limited liability company. SenlangBio is currently the largest cell therapy company in Northern China in terms of bio-manufacturing scale, breadth and depth of clinical development programs, and pre-clinical research.
Read the full article: Avalon GloboCare Announces Execution of Purchase Agreement for Acquisition of SenlangBio //
Source: https://www.globenewswire.com/news-release/2021/06/14/2246595/0/en/Avalon-GloboCare-Announces-Execution-of-Purchase-Agreement-for-Acquisition-of-SenlangBio-in-All-Stock-Transaction.html